Wanbangde Pharmaceutical Holding Group Co., Ltd.

Wanbangde Pharmaceutical Holding Group Co., Ltd. saw its stock price decline significantly amid a broader market downturn. Despite a strong year-over-year performance, the company faces challenges, including a substantial drop in net sales and operating profit, alongside a high debt-to-equity ratio and low return on equity.

Wanbangde Pharmaceutical Holding Group Co., Ltd. saw a notable stock increase today, contrasting with a decline in the broader market. While the stock has significantly outperformed the market over the past year, it faces challenges such as declining sales, high debt, and recent negative financial results.

Wanbangde Pharmaceutical Holding Group Co., Ltd. faced a significant decline in stock value, reaching an intraday low amid ongoing challenges. Despite a strong annual performance, the company has reported substantial drops in earnings per share and negative results in recent quarters, alongside high debt levels and low return on equity.

Wanbangde Pharmaceutical Holding Group Co., Ltd. saw its stock price decline today, contrasting with a slight dip in the China Shanghai Composite. Despite a recent weekly gain, the company faces long-term challenges, including significant decreases in net sales and operating profit over five years, alongside negative earnings trends.

Wanbangde Pharmaceutical Holding Group Co., Ltd. has seen notable stock performance, with a significant increase on March 10, 2026. Over the past year, the company has achieved a remarkable return, outperforming the China Shanghai Composite. However, it faces challenges such as high debt levels and declining sales and profits.

Wanbangde Pharmaceutical Holding Group Co., Ltd. saw a notable increase in its stock price on March 9, 2026, amid a declining market. The company has shown strong performance over the past month and year, but faces challenges such as high debt and declining sales, indicating a complex financial situation.

Wanbangde Pharmaceutical Holding Group Co., Ltd. saw a notable stock decline, contrasting with the broader market's performance. Despite impressive annual growth, the company faces challenges such as declining net sales and operating profit, alongside a concerning debt-to-equity ratio and low return on equity, with a market capitalization of CNY 11,008 million.